Free Trial

Evoke Pharma Q3 2023 Earnings Report

Evoke Pharma logo
$4.46 +0.06 (+1.36%)
As of 03:46 PM Eastern

Evoke Pharma EPS Results

Actual EPS
-$6.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$1.56 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Evoke Pharma Earnings Headlines

StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)
Evoke underscores committment to patients after FDA update on domperidone
7 Explosive Stocks Every Investor Needs for 2025
What if you could identify the next big stocks before everyone else? Our exclusive report, "7 Stocks to 10x: High-Growth Stocks Ready to Buy for 2025," highlights the best investment opportunities you won’t want to miss.
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat